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Abstract Pretermdelivery is associatedwith neurodevelopmental
impairment caused by environmental and genetic factors.
Dysfunction of the excitatory amino acid transporter 2
(EAAT2) and the resultant impaired glutamate uptake
can lead to neurological disorders. In this study, we in-
vestigated the role of single nucleotide polymorphisms
(SNPs; g.-200C>A and g.-181A>C) in the EAAT2 pro-
moter in susceptibility to brain injury and neurodisability
in very preterm infants born at or before 32-week gesta-
tion. DNA isolated from newborns’ dried blood spots
were used for pyrosequencing to detect both SNPs.
Association between EAAT2 genotypes and cerebral palsy,
cystic periventricular leukomalacia and a low develop-
mental score was then assessed. The two SNPs were con-
cordant in 89.4% of infants resulting in three common
genotypes all carrying two C and two A alleles in differ-
ent combinations. However, in 10.6% of cases, non-
concordance was found, generating six additional rare ge-
notypes. The A alleles at both loci appeared to be detri-
mental and consequently, the risk of developing cerebral
palsy increased four- and sixfold for each additional det-
rimental allele at -200 and -181 bp, respectively. The two
SNPs altered the regulation of the EAAT2 promoter activ-
ity and glutamate homeostasis. This study highlights the
significance of glutamate in the pathogenesis of preterm
brain injury and subsequent development of cerebral palsy
and neurodevelopmental disabilities. Furthermore, the de-
scribed EAAT2 SNPs may be an early biomarker of vul-
nerability to neurodisability and may aid the development
of targeted treatment strategies.
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Introduction
Progress in perinatal care over the last three decades has led to
greater survival rates in infants born prematurely [1, 2]. The
incidence of premature birth in developed countries varies
from 7.6–12% of all births [3]. While 90% of very preterm
infants (below 32-week gestation) now survive beyond the
postpartum period, ~35% have neurodisabilities [4]. These
disabilities include cerebral palsy, cognitive- and behavioural
problems [5]. The estimated cost of preterm birth throughout
childhood in England and Wales with a birth rate of 700,000/
year is around £3 billion per annum [6]. Susceptibility of a
preterm infant to neurodisability is difficult to predict, shows
considerable variation between individuals [7] and is likely to
be modulated by genetic factors [8]. Better diagnostic ap-
proaches for the early identification of infants with higher risk
of neurodisability are important to facilitate the development
and application of appropriate treatment strategies.
Much of the neurodisability seen in very preterm infants is
caused by white matter injury, known as periventricular
leukomalacia (PVL) and the subsequent disruption of normal
neural connectivity [9]. While the pathogenesis of PVL re-
mains to be established, in vitro and in vivo animal stud-
ies have identified important roles for oxidative stress,
cytokine-mediated injury and glutamate-induced
excitotoxicity [10, 11]. Following hypoxia-ischaemia, the
excitatory neurotransmitter glutamate is released into the
extracellular space, causing over-activation of ionotropic
glutamate receptors present in pre-myelinating oligoden-
drocytes [12], which induces their excitotoxic cell death
and subsequent white matter lesions [10].
In the brain, neuronal and glial excitatory amino acid trans-
porters (EAATs) play a key role in maintaining extracellular
glutamate below neurotoxic levels. The activity of the pre-
dominantly astroglial high-affinity glutamate transporter
EAAT2 (also known as solute carrier family 1 member 2-
SLC1A2 or the rodent ortholog glutamate transporter 1-GLT-
1) is responsible for 90% of total glutamate uptake [13, 14].
Furthermore, EAAT2 has been implicated in the pathology of
cerebral ischemia [15]. While ischaemic brain injury was ex-
acerbated in transgenic mice lacking the EAAT2 protein in the
brain [16], upregulation of EAAT2 provides neuroprotection
[15]. EAAT2 is widely expressed in the white matter of the
developing human brain [17] and upregulated in reactive as-
trocytes in post-mortem brain tissue of preterm infants with
PVL, which may indicate a response to either hypoxic-
ischemic injury or inflammation [18]. Collectively, these find-
ings suggest that dysregulated EAAT2 activity may contribute
to white matter damage.
A functional single nucleotide polymorphism (SNP) in the
promoter region of the EAAT2 gene has been associated with
higher serum glutamate levels in adults and consequently a
worse neurological outcome after stroke [19] and also with
relapsing multiple sclerosis [20]. These studies raised the in-
triguing possibility that similar genetic differences may en-
hance predisposition to neurodevelopmental impairment after
preterm birth. The aim of this study was to establish the role of
two closely linked functional SNPs in the EAAT2 gene pro-
moter [19, 21] in susceptibility to brain injury and
neurodisability in very preterm infants.
Materials and Methods
Patient Selection
The risk of CP in infants born <33 weeks of gestation is 30
times higher than among those born at term [22]. Therefore,
our study included infants born at this vulnerable period.
Newborns’ dried blood spots and clinical data were obtained
from all infants born ≤32 weeks of gestation and survived to
discharge in the South West of England recruited to the
Avon Premature Infant Project (APIP; 1990–1993,
n = 329 [23]) or received care within the neonatal unit
of Gloucestershire Royal Hospital (2002–2008;
n = 127); Southmead Hospital, North Bristol NHS
Trust (2005–2010; n = 169) or St Michael’s Hospital,
University Hospitals Bristol NHS Trust (2002–2008;
n = 196). Infants with major congenital anomalies of
the central nervous system and genetic syndromes that
may cause neurodevelopmental impairment or cerebral
palsy were excluded. The archived blood spots were
fully anonymised according to the Human Tissue Act
and Medical Research Council (UK) Guidance and used
for research without individual informed consent as per-
mitted by the UK newborn screening programme Code
of Practice for the retention and Storage of Residual
Spots (April 2005, ISBN 0955013801). From the total
(n = 821 infants), 208 blood spots were not traceable, 1
was excluded with a chromosomal abnormality, ten
DNA samples failed all pyrosequencing assays and 61
infants had no outcome data, leaving a total of 541
infants for the analyses (Table 1).
Sample Collection and DNA Isolation
Blood was collected from heel prick blood sampling on blood
spot screening cards prepared routinely within 5–8 days of
birth as part of the UK Newborn Screening Programme
[http://newbornbloodspot.screening.nhs.uk]. DNA was
isolated as described previously [24].
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Generation of Biotinylated PCR Products
for Pyrosequencing
Two sequence-specific primers (EAAT2PyroF-BIO and
EAAT2PyroR; Table 2) were designed to amplify a 166 bp
region of the EAAT2 promoter which included the two SNPs
rs111885243:C>A or g.-200C>A (at positions -200 bp) and
rs4354668:a>c or g.-181A>C (at position -181 bp) using the
software provided by Qiagen Pyrosequencing. The 5′ end of
the forward primer was modified with biotin. PCR reactions
contained 4–6 ng of genomic DNA, 1× PCR buffer (100 mM
Tris-HCl, 500 mM KCl pH 8.3), 1.5 mM MgCl2, 200 μM of
each dNTP, 100 pmol of each oligonucleotide and 1 unit of
high-fidelity Taq polymerase (FastStart High Fidelity Taq
Polymerase, Roche Diagnostics Limited, West Sussex, UK)
per reaction. Amplification was performed as follows: 95 °C
for 5 min, 50 cycles of 94 °C for 30 s, 60 °C for 30 s, 72 °C for
30 s and final extension 72 °C for 10 min. Two additional
SNPs, rs116392274 in EAAT2 and rs1835740 [21], which
are involved in glutamate homeostasis, were also analysed in
the cohort and data are shown as Supplementary materials.
Pyrosequencing and Sanger Sequencing
All steps were carried out as previously described (Table 2)
[21, 24]. Genotypes of randomly selected samples (n = 51)
from pyrosequencing were confirmed by Sanger sequencing
(using ABI 3730xl 96 capillary DNA Analyzers) at Eurofins
MWG Operon (Ebesberg, Germany).
Primary Astrocyte Cultures and Preparation
of the EAAT2 Promoter Constructs
Primary rat astrocytes were separated from mixed glial cul-
tures of embryonic (E20) Sprague-Dawley rat brains (Harlan,
UK) using the previously described selective detachment
Table 1 Birth-related information and neurodevelopmental outcomes (n = 541). Values are numbers with % or means ± standard deviation, as
appropriate. All measures were analysed independently so denominator may vary
Measure Avon Premature Infant Project (APIP;
n = 228)
Gloucestershire Royal Hospital
(n = 90)
Southmead Hospital
(n = 81)
St Michael’s Hospital
(n = 142)
Gestational age
(week)
29.9 (±2.0) 27.8 (±2.2) 26.8 (±1.8) 27.4 (±1.7)
Birth weight (g) 1435 (±384) 1130 (±347) 916 (±278) 992 (±404)
Male 131 (57.5%) 44 (49.4%) 42 (52.5%) 69 (50.4%)
Multiple birth 48 (21.1%) 27 (30.0%) 29 (36.3%) 35 (25.6%)
White ethnicity 209 (92.1%) 80 (90.9%) – 44 (81.5%)
Apgar score
1 min 6.3 (±2.2) 6.2 (±2.1) 5.7 (±2.1) 6.3 (±2.1)
5 min 8.5 (±1.6) 8.4 (±1.5) 7.6 (±2.1) 8.4 (±1.4)
Cerebral palsy 19 (8.3%) 12 (14.0%) – 10 (8.4%)
Cystic PVL 18 (8.1%) 6 (6.9%) 7 (8.6%) 6 (4.4%)
Low developmental
score
16 (8.0%) 9 (10.2%) – 17 (16.4%)
Table 2 Pyrosequencing primers
and reaction conditions used in
the study
Oligonucleotide Sequence 5′-3′ Product (bp) Annealing T (°C) Modifications
EAAT2PyroF-BIO
EAAT2PyroR
GGGGCTAAACCTTGCAATC
GAGTGGCGGGAGCAGAGA
166 60 5′ Biotin
None
EAAT2PyroSeq GGGTGTGTGCGCGCC N/A None
Target sequence for pyrosequencing T/GGGGGAGGCGGTGGAGGCCG/TCTG
Nucleotide dispensation order CGTGCAGCGTGAGCGTGC
Primer pair EAAT2PyroF-BIO/EAAT2PyroR were used to generate biotinylated PCR products flanking SNPs g.-
200C>A and g.-181A>C. Primer EAAT2PyroSeq was used for pyrosequencing. The target sequence and the
order of nucleotide dispensation for the pyrosequencing assay are listed. In the dispensation order the nucleotides
used as negative controls are underlined. In optimal pyrosequencing conditions, these nucleotides are not incor-
porated into the target DNA sequence and therefore their addition do not generate peaks on the pyrogram (Fig. 1).
The nucleotide change in the target sequence for pyrosequencing is indicated in bold
N/A not available
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(shaking) method [25]. Following separation at day 10
in vitro, astrocytes were maintained in T75 cell culture flasks
(Corning Incorporated, New York, USA) at 37 °C in a humid-
ified 5% CO2: 95% air atmosphere. Cells were cultured in
Dulbecco’s modified Eagle’s medium (Sigma Aldrich, MO,
USA) containing 4.5 g/l glucose, 29 mM sodium bicarbonate,
50 U/ml penicillin, 50 μg/ml streptomycin (Sigma Aldrich,
MO, USA) and 10% (v/v) foetal bovine serum (Life
Technologies Ltd., Paisley, UK). Glial fibrillary acidic protein
immuno-labelling and trypan blue staining [26, 27] were used
to confirm the purity and viability of the astrocyte cultures.
Previously described oligonucleotides were used to amplify a
773 bp fragment of the EAAT2 promoter [19]. Genomic DNA
of genotype 1 and genotype 3 was amplified in 25μl reactions
containing 2 μl genomic DNA, 1X High Fidelity PCR buffer
(100 mM Tris-HCl, 500 mM KCl pH 8.3), 1.5 mM MgCl2,
200 μM of each dNTP, 100 pmol of each oligonucleotide and
1 unit of high-fidelity Taq polymerase (FastStart High Fidelity
Taq Polymerase, Roche Diagnostics Limited, West Sussex,
UK). Amplification was performed as follows: 1 cycle at
95 °C for 5 min, 35 cycles of 94 °C for 30 s, 65 °C for 30 s,
72 °C for 1 min and final extension at 72 °C for 10 min.
Following enzyme digestion and fragment purification, the
promoter fragment was inserted upstream of the firefly lucif-
erase reporter in the pGL3-basic luciferase reporter vector.
Transfection of Astrocytes and Luciferase Reporter Gene
Assay
Cells were seeded at a density of 1 × 105 per well in 1 ml of
complete growth medium in a 12 well plate (Corning
Incorporated, New York, USA) 24 h prior to transfection. At
>80% confluency, the cells were transfected using 1 μg of
EAAT2 promoter construct (EAAT2PrWT -200 bp C/C -
181 bp A/A or EAAT2PrMT -200 bp A/A -181 bp C/C) and
10 μl of TransIT®-Neural Transfection Reagent (Mirus Bio,
Madison, WI 5371, USA) in Opti-MEM® I Reduced Serum
Media (Life Technologies Ltd., Paisley, UK). One hundred
nanograms of pRL-thymidine kinase plasmid (Promega, WI,
USA) containing the Renilla luciferase gene was co-
transfected with each construct and used as an internal control.
Forty-eight-hour post-transfection, the cells were washed and
harvested for the promoter activity assay. All transfections
were carried out in triplicates and all experiments were repeat-
ed three times.EAAT2 promoter activity was determined using
the Dual-Luciferase Reporter (DLR) Assay System (Promega,
WI, USA) following the manufacturer’s guidelines.
Patient Outcome Measures
The primary outcome measure was the diagnosis of cerebral
palsy. Cerebral palsy was diagnosed when a disorder of move-
ment and posture causing activity limitation were present at
clinical examination performed at 2 years of age [28]. The
secondary outcome measures were (i) cystic PVL diagnosed
on a cerebral ultrasound scan during the neonatal stay and (ii)
a low developmental score using standardised developmental
assessment tools at 2 years of age. Cerebral ultrasound scans
were performed as part of routine clinical monitoring by the
clinicians in all four groups of infants. Cystic PVL was diag-
nosed as standard [29] (i.e. when any cystic changes were
visible in the periventricular white matter on ultrasound).
Standardised developmental assessment data was available
for three of the four infant groups (Table 3). The Griffith
Mental Developmental Scale [30] was used for the APIP
and the Gloucestershire Royal Hospital group, while the
Bayley Scales of Infant Development (BSID) score (initially
version II to 2006, version III after 2006 to-date) [31, 32] for
the St Michael’s Hospital group. BSID-II is divided into two
subscales (i) cognitive (Mental Developmental Index; MDI)
and (ii) motor (Psychomotor Developmental Index; PDI). The
updated BSID-III has three subscales: cognitive, language and
motor PDI. Infants falling in the lowest 10th centile for either
the main score (Griffith) or any of the subscales (BSID) in
Table 3 Summary
neurodevelopmental scores and
standardised assessment used.
Results are median (interquartile
range-IQR). The standardised
neurodevelopmental assessment
scales used were: Griffith Mental
Developmental Scale [30],
Bayley Scales of infant
development 2nd edition (BSID-
II) [31] and 3rd edition (BSID-III)
[32]. (For details, see the
BMaterials andMethods^ section)
Developmental assessment used Median (IQR) ‘Low developmental score’—
10th percentile cut-off
APIP
Griffith Mental Developmental Scale 96 (90–105) <82
Gloucestershire Royal Hospital
Griffith Mental Developmental Scale 101 (90–111) <64
St Michael’s Hospital
BSID-II-Mental Developmental Index 94 (70–108) <51
BSID-II-Psychomotor Developmental Index 87 (71–100) <53
BSID-III-Cognitive Developmental Index 100 (85–110) <76
BSID-III-Language Developmental Index 96 (85–103) <76
BSID-III-Psychomotor Developmental Index 96 (89–107) <84
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each infant group were defined a priori as having a low devel-
opmental score. Birth weight, gestational age at birth and
physiological condition during the first 5 min after birth
(Apgar scores at 1 and 5 min) were considered a priori possi-
ble confounders.
Statistical Analysis
Initially, the perinatal/intrapartum characteristics (gestation,
birth weight, gender, multiple births, ethnicity and Apgar
score) of the population were assessed, split by their genotype.
Then, univariable associations were assessed, between the two
EAAT2 genotypes and the primary and secondary outcome
measures (see previous section). Due to the data coming from
multiple infant groups with different developmental tools,
multi-level logistic regression models were derived using the
Stata 10 (Stata Corp, TX, USA) Bxtlogit^ command, to inves-
tigate the association of the odds of each additional polymor-
phic allele and the outcomemeasures. Adjustment for possible
confounders was performed by adding the perinatal/
intrapartum variables described above to the logistic regres-
sion models as continuous variables. Two sensitivity analyses
were performed: (i) the analysis was repeated using single-
level (rather than multi-level) modelling, and (ii) the missing
covariates were imputed to allow the adjusted analysis to
contain the same number of individuals as the unadjusted.
Genotypes or outcome data was not imputed. Imputation
was performed using multiple imputation with chained equa-
tions [33]. Details of imputation technique are available on
request. All analyses were conducted with Stata 10 (Stata
Corp, TX, USA) or Excel (Microsoft Corp, WA, US). All data
are presented as odds ratio (OR) (95% confidence interval
(CI)), mean (SD) or number (percent (%)).
Results
Simultaneous Pyrosequencing of Two SNPs in the EAAT2
Promoter
A functional SNP was reported previously in the EAAT2 pro-
moter at -181 bp (rs4354668) [19]. Our detailed investigation
of the EAAT2 promoter using Sanger sequencing revealed
another SNP, 19 bp upstream of rs4354668, at position -
200 bp (rs111885243) [21]. These two SNPs cannot be distin-
guished by single-strand conformational polymorphism used
in the previous study [19]; therefore, a pyrosequencing assay
was developed (Fig. 1). All traceable blood spots were
analysed (n = 613) by pyrosequencing and 521 produced clear
pyrograms. Ten percent of these samples (n = 51) were
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Fig. 1 Pyrograms of the EAAT2 promoter SNPs. The position of the
SNPs is highlighted in yellow boxes, the x-axis of each pyrogram
indicates the order of reagent addition (E-enzyme, S-substrate and
nucleotide A, G, T or C); the y-axis shows the light intensity generated.
The numbering of pyrograms corresponds to the genotype numbers in
Table 2. Due to the high GC content of the target sequence and the four C
repeats before the SNP at position -181 bp, the pyrosequencing was
carried out on the reverse strand. Thus, note that the sequence is in
reverse orientation
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sequenced and the concordance with pyrosequencing was
100%. In total, 471 of the infants had clinical outcome avail-
able for the analysis of rs4354668 and rs4354668.
Distribution of Different Alleles in the Study Population
Nine genotype combinations were identified (Table 4 and
Fig. 1). In 419 samples (88.9%), the two SNPs were in linkage
disequilibrium (p < 0.001). Linkage disequilibrium was not
complete and hence the nine different genotypes (Table 4).
The majority of alleles demonstrated high levels of concor-
dance, such that if the -200 locus was homozygous (C/C or
A/A), the -181 locus was also homozygous (A/A or C/C) and
if -200 locus was heterozygous, the -181 locus was heterozy-
gous as well (Table 4; genotypes 1–3). In the rarer genotypes
(11.0% of the cases, Table 4; genotypes 4–9), the alleles were
non-concordant between the two polymorphic loci. We inves-
tigated rs116392274 (g.-168C>T) in the EAAT2 promoter in
the cohort but apart from one infant, who was a heterozygote,
all others carried C/C alleles. Allele distribution of rs1835740
is shown in Supplementary materials.
EAAT2 Promoter Activity
To analyse the functional effects of the -200 C>A; -181A>C
SNPs on transcriptional activity in vitro, genotype 1 (-200 C/
C; -181 A/A) or genotype 3 (-200 A/A; -181 C/C) reporter
constructs were transiently transfected into primary as-
trocytes, together with the pRL-TK vector as an internal
control that constitutively expresses the Renilla lucifer-
ase. The genotype 1 promoter construct displayed be-
tween 4- and 4.7-fold greater activity compared with
the genotype 3 construct (p < 0.0015; Fig. 2).
Several attempts were made to measure the promoter ac-
tivity of genotypes 5 and 8 using initially the three clinical
samples that carried these genotypes (Table 4). These blood
samples were 15–20 years old and the isolated gDNA and the
resulting PCR products were of insufficient quality [24]
for successful ligation to produce the required promoter
constructs. In an alternative approach, we attempted to
generate these variants using site directed mutagenesis
of genotypes 1 and 3. However, due to the very high
GC content of the promoter amplicon (over 70%; [34]),
no correct mutants were obtained.
Characteristics of the Cohort
The intrapartum/perinatal characteristics of the eligible infants
split by groups or genotypes are shown in Tables 1 and 5.
Importantly, the patient outcome measures (e.g.: the rate of
cerebral palsy (p = 0.284), cystic PVL (p = 0.553) and low
developmental scores (p = 0.084)) did not differ between the
four groups investigated (Table 1) and thus were combined for
subsequent analysis. An association between ethnicity and
genotype was observed (p < 0.001) when the whole cohort
was investigated (Table 5). To better understand the nature of
the association between ethnicity and the two SNPs, the co-
hort was investigated in more details. While there was no
difference in the individual frequencies at the two SNPs by
ethnicity (-181, p = 0.206 and -200, p = 0.854), white infants
were more likely to show the concordance discussed above
than non-white infants (94.6 vs. 76.1%, p < 0.001). Data on
ethnicity was available for three of the four infant groups
(Table 1) and within this population of preterm infants, there
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Fig. 2 Promoter activity of EAAT2. Astrocytes were transiently
transfected with sequences corresponding to genotype 1 (-200 C/C; -
181 A/A) and 3 (-200 A/A; -181 C/C) reporter constructs. Firefly and
R. reniformis luciferase activities were measured as detailed in the
BMaterials and Methods^ section and the relative firefly/Renilla lucifer-
ase values are shown. Bars represent relative luciferase values from three
independent experiments with standard deviation
Table 4 Distribution of genotypes in the sample cohort. Genotypes
were identified by pyrosequencing and confirmed by Sanger
sequencing (n = 51)
Genotype Genotype -200C>A -181A>C Number and proportion
1 C/C A/A 95 (20.2%)
2 C/A A/C 261 (55.4%)
3 A/A C/C 63 (13.4%)
4 C/A A/A 9 (1.9%)
5 A/A A/A 2 (0.4%)
6 C/C A/C 19 (4.0%)
7 A/A A/C 8 (1.7%)
8 C/C C/C 1 (0.2%)
9 C/A C/C 13 (2.8%)
Allele frequency C = 0.56
A = 0.44
A = 0.53
C = 0.47
n = 471
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was strong evidence of deviation from the Hardy-Weinberg
equilibrium (p < 0.001).
Outcome Measures
In the univariable analyses (in which associations were
assessed between each of the EAAT2 SNP and the primary
and secondary outcome measures independently), there was
no clear evidence for an association between different alleles
with cerebral palsy, cystic PVL or a low developmental score
(Table 6). However, when adding both polymorphisms into
the multivariable analysis, the presence of A alleles at -181
and -200 bp appeared to increase the likelihood of a low de-
velopmental score with OR of 4.56(1.53–13.60) and
3.73(1.29–10.80), respectively (Table 7; unadjusted (1)).
This association persisted in the analysis adjusted for gesta-
tion, birth weight, gender and physiological condition at birth
(Table 7; adjusted (2)). In contrast, there was less evidence for
any association between either allele and cerebral palsy or
cystic PVL. Due to the association seen with ethnicity
(Table 5), this covariate was added to the model in a final
adjusted analysis (Table 7; adjusted (3)). In this final model,
the association with cerebral palsy strengthened with each
additional A allele (locus -200 bp OR 4.34 (1.12–16.77) and
locus -181 bp OR 6.64(1.76–25.07)), although there was less
evidence that the polymorphism at locus -200 bp remained
associated with an increased risk of a low developmental score
(OR 2.84 (0.71–11.44)). Repeating the analysis using a model
where the missing covariate data was imputed, the results
were compatible with the main analysis. The single infant
who was a heterozygote for rs116392274 had no CP or a
low developmental score. Similarly, no association was ob-
served between rs1835740 and CP or a low developmental
score (Supplementary Materials).
Discussion
SNPs in EAAT2 Promoter Are Associated
with Neurodevelopmental Impairment After Preterm
Birth
To our knowledge, this is the first study that demonstrates
association between genetic variants of EAAT2 involved in
Table 5 Intrapartum/perinatal characteristics of the cohort
Perinatal measure n -200C>A -181A>C p
CC AC AA AA AC CC
Gestation (week) 466 28.5 (±2.3) 28.4 (±2.4) 29.0 (±2.3) 28.6 (±2.4) 28.4 (±2.3) 28.7 (±2.5) 0.673
Birth weight (g) 466 1217 (±402) 1182 (±437) 1267 (±466) 1218 (±403) 1185 (±438) 1254 (±462) 0.690
Male 465 63 (56.8%) 147 (52.7%) 40 (54.8%) 59 (56.2%) 149 (52.7%) 42 (54.6%) 0.525
Multiple birth 466 28 (24.6%) 68 (24.4%) 22 (30.1%) 24 (22.9%) 75 (26.4%) 19 (24.7%) 0.268
White ethnicity 333 78 (91.8%) 183 (90.2%) 40 (88.9%) 77 (93.9%) 180 (90.5%) 44 (84.6%) <0.001
Apgar score
1 min 452 6.1 (±1.9) 6.3 (±2.2) 6.1 (±2.1) 6.1 (±2.0) 6.3 (±2.1) 6.0 (±2.2) 0.526
5 min 451 8.3 (±1.5) 8.3 (±1.7) 8.3 (±1.6) 8.3 (±1.5) 8.4 (±1.6) 8.2 (±1.7) 0.769
n-number of infants with data available. Values are numbers with % or means ± standard deviation, as appropriate
Table 6 Univariable associations
between genotype and outcome
measures
Outcome measure n Homozygote Heterozygote Homozygote p
-200C>A CC AC AA
Cerebral palsya 385 9 (9.6%) 23 (9.7%) 3 (5.6%) 0.621
Cystic PVL 458 7 (6.3%) 21 (7.6%) 3 (4.2%) 0.566
Low developmental scorea 349 7 (7.7%) 26 (12.4%) 3 (6.3%) 0.286
-181A>C AA AC CC
Cerebral palsya 385 10 (11.4%) 23 (9.5%) 2 (3.9%) 0.263
Cystic PVL 458 7 (6.7%) 20 (7.3%) 4 (5.2%) 0.817
Low developmental scorea 349 11 (12.9%) 22 (10.3%) 3 (5.9%) 0.424
n-number of infants with data available. Values are numbers with %
aCerebral palsy and low developmental score data were only available from three cohorts (for details, see Table 1)
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maintaining glutamate homeostasis and neurodevelopmental
impairment in very preterm infants.We identified that SNP g.-
200C>A in the EAAT2 promoter is strongly linked to the pre-
viously described functional SNP g.-181A>C [19], which has
not been reported in earlier studies [19, 20, 35]. The A alleles
at both loci appear to increase the risk of cerebral palsy and
low developmental scores (Table 7). In the common concor-
dant inheritance pattern (Table 4, genotypes 1–3), the protec-
tive C and detrimental A alleles are usually inherited to-
gether whereas in the rare non-concordant genotypes, only
detrimental alleles (Tables 4 and 8, genotypes 4/5/7) or just
protective alleles (Tables 4 and 8, genotypes 6/8/9) were
found at both loci. This concordance was more likely with
white ethnicity. Due to the strong linkage between the two
SNPs, it was appropriate to enter both into the multi-level
regression analysis to assess the impact of increasing det-
rimental A alleles. In the multi-level regression analysis
(Table 7), adjustment for gestation, birth weight, gender,
multiple births and Apgar scores made no significant dif-
ference to the odds of any of the outcome measures.
However, the addition of ethnicity into the regression anal-
ysis strengthened the effect seen on cerebral palsy at both
loci. In addition, the odds of a low developmental score
were also significantly increased with each A allele at -
181 bp. To put this in context, for each additional A allele
at -181 or -200, the odds of cerebral palsy increased by
about four- and sixfold and the odds of a low developmen-
tal score increased fourfold. The prevalence of cerebral
palsy or a low developmental score was as high as 28
and 44% for genotypes 7 and 4 with three detrimental al-
leles, respectively (Table 8). In contrast, no association was
observed between rs116392274 or rs1835740 and CP or a
low development score in the cohort indicating that these
SNPs are unlikely to play important roles in the injury of
the developing brain (Supplementary materials).
Regulation of EAAT2 Promoter Activity
These two SNPs significantly affect EAAT2 promoter activity
in vitro. The promoter fragment -742/+31 [19] containing -
200A/A -181C/C sequence (genotype 3) showed a 70–80%
reduction in basal EAAT2 promoter activity compared to -
200C/C -181A/A (genotype 1; Fig. 2). This is a larger impact
than the previously reported ~30% reduction [19]; however, in
that study, the SNP at position -200 bp was not identified and
it is not clear which nucleotide was present in their promoter
construct. The change from A to C at -181 bp abolishes the
binding site for transcription factor AP-2 (activating enhancer
binding protein 2) and creates a site for GC-binding factor 2
(GCF2) which represses EAAT2 expression (Fig. 3; [19]).
Reduced EAAT2 expression alters extracellular glutamate
levels [13]. Despite the large difference in EAAT2 promoter
activity between genotypes 3 and 1, there was no clear asso-
ciation with low developmental score or cerebral palsy in any
of the main three genotypes (Table 8; genotypes 1–3). Similar
observations were made in patients with multiple sclerosis
[20] and migraine [36] where the allele and genotype frequen-
cies for the EAAT2 promoter polymorphism were similar in
patients and controls. However, the polymorphism at -181 bp
was associated with higher plasma glutamate concentrations
during relapsing multiple sclerosis [20].
Gene expression in the nervous system is not only con-
trolled by the transcriptional machinery, but it is also sub-
ject to modulation by epigenetic mechanisms such as DNA
methylation [36, 37]. Dynamic DNA methylation is ob-
served during brain development [38, 39] and the levels
of DNA methylation are increased upon ischemic injury
[40]. Recent studies revealed that the basal transcriptional
activity of the EAAT2 gene is controlled by DNA methyl-
ation of cytosine residues in the region of -1010 to -1 bp of
the EAAT2 promoter [41, 42]. Hypermethylation of the
Table 7 Multi-level regression analysis for presence of each increasing -200 or -181 A allele and outcomes
Outcome measure Unadjusted (1) Adjusted (2) Adjusted (3)
n OR (95% CI) p n OR (95% CI) p n OR (95% CI) p
-200C>A
Cerebral palsy 385 1.70 (0.62–4.66) 0.299 365 1.68 (0.57–4.94) 0.346 314 4.34 (1.12–16.77) 0.033
Cystic PVL 458 0.88 (0.30–2.58) 0.812 444 0.82 (0.26–2.60) 0.740 317 0.68 (0.13–3.50) 0.641
Low developmental score 349 3.73 (1.29–10.80) 0.015 329 3.23 (1.04–10.02) 0.042 282 2.84 (0.71–11.44) 0.142
-181A>C
Cerebral palsy 385 2.44 (0.87–6.79) 0.089 365 2.72 (0.90–8.22) 0.083 314 6.64 (1.76–25.07) 0.005
Cystic PVL 458 1.00 (0.32–3.13) 0.812 444 0.99 (0.31–3.10) 0.980 317 0.88 (0.18–4.31) 0.870
Low developmental score 349 4.56 (1.53–13.60) 0.007 329 3.93 (1.23–12.57) 0.013 282 4.15 (1.05–16.38) 0.042
(1)Multi-level for neonatal unit of care and developmental tool used. (2) Adjusted for gender, birth weight, gestation and Apgar scores at 1 and 5min. (3)
Additionally adjusted for ethnicity. n—number of infants with data available. Values are odds ratio (95% confidence interval)
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EAAT2 promoter is involved in repression of EAAT2 acti-
vation [42]. Furthermore, a recent study revealed signifi-
cant differences in the methylation of ten genes involved in
neuronal and glial signalling, neurotransmission, apoptosis
and cellular energetics between preterm and term infants
[43]. Importantly, among these genes was EAAT2, which
promoter was differentially methylated at multiple CpG
sites. Additionally, significant variation of EAAT2
promoter activity was observed in different brain regions
and even between neighbouring cells [44]. These findings
indicate that EAAT2 promoter is dynamically regulated un-
der physiological conditions. In genotypes 4/5/7, the C
alleles at both -200 and -181 bp are replaced partially or
fully by A alleles (Table 8), which might interfere with the
normal methylation process and the binding of GCF2 tran-
scription factor to the EAAT2 promoter [19] (Fig. 3).
Table 8 EAAT2 genotypes and outcomes
Genotype Low developmental score Cerebral palsy Low developmental score
OR cerebral palsy
A alleles Genotype
code
SNP
-200 bp
SNP
-181 bp
Number with outcomes % Number with outcomes % Number with at least
one outcome
%
0 8 C/C C/C 0 – 0 – 0 –
1 9 C/A C/C 10 1 (10.0%) 10 0 (0.0%) 10 1 (10.0%)
1 6 C/C A/C 14 0 (0.0%) 16 1 (6.3%) 16 1 (6.3%)
2 3 A/A C/C 41 2 (4.9%) 46 2 (4.4%) 46 4 (8.7%)
2 2 C/A A/C 192 21 (10.9%) 218 21 (9.6%) 220 32 (14.6%)
2 1 C/C A/A 77 7 (9.1%) 78 8 (10.3%) 80 10 (12.5%)
3 7 A/A A/C 7 1 (14.3%) 7 1 (14.3%) 7 2 (28.6%)
3 4 C/A A/A 8 4 (50.0%) 9 2 (22.2%) 9 4 (44.4%)
4 5 A/A A/A 0 – 1 0 (0.0%) 1 0 (0.0%)
AP2 GCF2Activation Repression
A
C
Methylated (Inactive)
Un-methylated (Active)
ON
TF
-200 -181 bp
CC
Un-methylated (Active)
ON
TF
-200 -181 bp
AA
TF
X
OFF
-200 -181 bp
CC
-200 -181 bp
AA
-200 -181 bp
CC
X
B
D
Fig. 3 Proposed model of the SNPs impact on EAAT2 gene regulation. a
EAAT2 promoter contains a consensus binding site for transcription factor
activating enhancer binding protein 2 (AP-2), which is an activator of
transcription in the developing brain [53]. b Nucleotide change from A
to C at -181 bp abolishes this AP-2 consensus sequence and creates a
binding site for transcription factor GC-binding factor 2 (GCF2) which
represses EAAT2 gene expression [19]. c, d EAAT2 promoter is not only
controlled by the transcriptional machinery, but is also subject to
modulation by epigenetic mechanism such as DNA methylation at CpG
dinucleotides that inhibits gene expression [38, 39, 41, 42]. DNA meth-
ylation is reversible and subject to dynamic regulation throughout em-
bryogenesis. Nucleotide changes from C to A might interfere with the
normal DNA methylation process of EAAT2 at both -200 and -181 bp,
affecting gene expression. The ability to downregulate EAAT2 in the
developing brain seems beneficial since infants with three C alleles have
better outcomes than those with only one
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Regulation of Glutamate Level by EAAT2
in the Developing Brain
One major pathology associated with cerebral palsy is PVL
[10]. Oligodendrocyte cell death is particularly prominent fol-
lowing hypoxia-ischemia, which leads to hypomyelination
[9]. Although the causes of PVL are not completely under-
stood, cerebral ischemia is likely to play an important role [9,
10] implicating glutamate excitotoxicity, and excessive acti-
vation of ionotropic glutamate receptors [12]. The regulation
of glutamate concentration in the extracellular space by
EAAT2 is therefore essential for normal synaptic function
[13] as well as neuronal survival by preventing excitotoxicity
[16]. However, when there is a dissipation of electrochemical
gradients across the plasma membrane as occurs during hyp-
oxia-ischemia, EAAT2 operates in reverse to release gluta-
mate, thereby promoting excitotoxicity [45]. In a rat model,
glutamate was reduced in oligodendrocytes and axons follow-
ing hypoxia-ischemia suggesting that these are the main
sources of glutamate in developing white matter [46].
Furthermore, EAAT2 deficient mice are more vulnerable to
neuronal loss in the hippocampus following a short episode of
ischemia, while the wild-type mice are more vulnerable to
neuronal death following prolonged ischaemia [47]. These
findings suggest that in prolonged ischaemia, EAAT2 be-
comes the major contributor to abnormal concentrations of
extracellular glutamate. EAAT2 expression is limited primar-
ily to oligodendrocytes early in development and is increased
during the period when the premature infant is most vulnera-
ble to PVL [17]. Furthermore, the EAAT2 protein level was
found to increase substantially in some cases of PVL com-
pared to age-related controls [18]. Similarly, a recent study
showed that EAAT2 is selectively expressed in cortical layer
V neurons that are damaged in premature infants with PVL
[48] and hypothesised that the reversal of glutamate transport
by EAAT2 together with hyperactivation of ionotropic gluta-
mate receptors contribute to excess ambient glutamate and
consequently cell death specifically in these neurons [49].
Taking together, these data indicate that in the developing
white matter, it is advantageous to have the ability to dynam-
ically downregulate EAAT2 expression during ischaemia. Our
genetic data supports this hypothesis; C alleles at -200 and/or -
181 bp allow for dynamic alteration of EAAT2 expression via
methylation and by the binding of GCF2 transcription factor
(Fig. 3). In contrast, in infants who carry mainly A alleles,
regulation of EAAT2 via these mechanisms is impaired,
which increases ischaemic vulnerability and subsequent im-
paired neurodevelopment and cerebral palsy.
Study Design Benefits and Limitations
This study included all infants of 32-week gestation or less,
including multiples who survived the first 5–8 days of life.
Consequently, preterm infants with severe brain injury due to
hypoxia-ischaemia or intraventricular haemorrhage, who of-
ten die in the first few days of life, were not included which
may explain the deviation from the Hardy-Weinberg equilib-
rium. Participants originated from four different infant groups/
neonatal centres in the SouthWest of England and included all
ethnic groups and therefore the findings are applicable to the
whole UK population of preterm infants. However, due to the
retrospective design of the study, not all bloodspots could be
traced from the complete population. The use of different
neurodevelopmental assessment tools for the different groups
precluded the use of raw cognitive or motor scores as contin-
uous variables. The pragmatic solution was to classify those in
the lowest 10th percentile of each group for each subscale/
score as having a low developmental score. The lowest 10th
percentile for each score translated as two standard deviations
below the normal population mean, which is widely accepted
as the cut-off for moderate/severe developmental impairment
when using a single developmental assessment tool in clinical
studies [50]. Cystic PVL was diagnosed on routine clinically
directed cerebral ultrasound and white matter injury was re-
ported and coded if it was severe and cystic in nature. We
included an extra group with cystic PVL data (Table 1;
Southmead Hospital) but despite increasing the power of the
analysis, there was no evidence for an association between the
SNPs tested and the measurable ultrasound changes. The
overall proportion of cystic PVL in this workwas 6.7%, which
is not statistically different from the population rate in the UK
Vermont Oxford dataset at the time (4.8%; p = 0.117). These
data suggest that milder (non-cystic) white matter injury may
not have been detected on clinical cerebral ultrasound in these
groups and consequently an association with EAAT2 geno-
type and white matter damage was not found. Magnetic reso-
nance imaging, which is more sensitive in detecting milder
grades of white matter injury [51], is not used routinely in
the UK to screen the preterm brain. These neuroimaging ap-
proaches performed in the first weeks of life are imprecise
surrogate markers of neurological function. Therefore, struc-
tured functional neurological assessment at 2 years for cere-
bral palsy and neurodevelopmental impairment (used in this
study) is considered to be the gold standard measure of neu-
rological outcome in preterm infants [52].
Conclusions
In this study, we have found that g.-200C>A and 181A>C
SNPs are associated with both clinical neurodevelopmental
outcomes and measurable in vitro effects on glutamate ho-
meostasis. These findings indicate that glutamate is likely
to be involved in the pathogenesis of brain injury and sub-
s e qu en t d e v e l o pmen t o f c e r e b r a l p a l s y a nd
neurodevelopmental impairments in the human infant. It is
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plausible that g.-200C>A SNP may also have a major ef-
fect on the development of neurological diseases in the
adult population as this SNP is so closely linked to the
g.-181A>C SNP, which was reported to affect neurological
function after adult stroke [19], multiple sclerosis [20] and
in schizophrenia [35]. The described EAAT2 SNPs may
have utility as a viable early biomarker of cerebral palsy
and long-term neurodisability in high-risk preterm infants.
These results warrant a prospective study with complete
recruitment (including non-survivors) to confirm the utility
as early biomarker of neurological outcome. Our results
also validate the notion that glutamate plays a pivotal role
in preterm brain injury and opens the debate around explo-
ration of glutamate uptake manipulation as potential phar-
macological intervention for the prevention of preterm brain
injury in infants with this genetic vulnerability. Better un-
derstanding of the dynamic transcriptional regulation of
EAAT2 during the perinatal period may be key to the fu-
ture development of effective clinical interventions.
Acknowledgements We would like to thank Dr. Helena Kemp for
assisting with tracing the dried blood spots from the screening archive,
Professor Neil Marlow for providing data on the Avon Premature Infant
Project (APIP) infants, Dr. Sam O’Hare and Dr. Manal el Bokle for
performing data collection on the Southmead Hospital infants and Dr.
Sally Jary for performing neurodevelopmental assessments on the St
Michael’s Hospital infants.
Author Contributions SR: study design, sample preparation for ex-
periments, pyrosequencing, data interpretation, manuscript preparation.
DO: patient data collection and analysis, statistical analysis, preparation
of manuscript. MTR: Promoter construct generation. ACS and LD: pri-
mary astrocyte generation and transfection for promoter assay. MW and
CC: pyrosequencing assay optimisation. DH, MWandMO: clinical sam-
ple and data collection. JC: manuscript preparation. EM, KL and AV:
conception, design of the study, manuscript preparation, supervision of
the experimental work, funding.
Compliance with Ethical Standards The study received ethical ap-
proval in April 2010 from the National Research Ethics Service, UK
(REC reference number 10/H0106/10).
Conflict of Interest EM is member of the Scientific Advisory Board of
Hello Bio [www.hellobio.com].
Funding This work was supported by the University of the West of
England, Bristol, UK (AV). EM is supported by the Biotechnology and
Biological Sciences Research Council, UK (grants BB/F011326/1 and
BB/J015938/1). The blood spot retrieval was funded by the David
Telling Charitable Trust (KL).
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
1. Field DJ, Dorling JS,ManktelowBN, Draper ES (2008) Survival of
extremely premature babies in a geographically defined population:
prospective cohort study of 1994-9 compared with 2000-5. Br Med
J 336:1221–1223. doi:10.1136/bmj.39555.670718.BE
2. Costeloe KL, Hennessy EM, Haider S, Stacey F, Marlow N, Draper
ES (2012) Short term outcomes after extreme preterm birth in
England: comparison of two birth cohorts in 1995 and 2006 (the
EPICure studies). Br Med J 345:e7976. doi:10.1136/bmj.e7976
3. Galinsky R, Polglase GR, Hooper SB, Black MJ, Moss TJ (2013)
The consequences of chorioamnionitis: preterm birth and effects on
development. J Pregnancy 2013:412831. doi:10.1155/2013/
412831
4. Moser K, Macfarlane A, Chow YH, Hilder L, Dattani N (2007)
Introducing new data on gestation-specific infant mortality among
babies born in 2005 in England and Wales. Health Stat Q 2007
Autumn:13–27.
5. Wilson-Costello D, Friedman H, Minich N, Siner B, Taylor G,
Schluchter M, Hack M (2007) Improved neurodevelopmental out-
comes for extremely low birth weight infants in 2000-2002.
Pediatrics 119:37–45. doi:10.1542/peds.2006-1416
6. Mangham LJ, Petrou S, Doyle LW, Draper ES, Marlow N (2009)
The cost of preterm birth throughout childhood in England and
Wales. Pediatrics 123:e312–e327. doi:10.1542/peds.2008-1827
7. Marret S, Marchand-Martin L, Picaud J-C, Mascoët J-M, Arnaud
C, Rozé JC, Truffert P, Larroque B et al, EPIPAGE Study Group
(2013) Brain injury in very preterm children and neurosensory and
cognitive disabilities during childhood: the EPIPAGE cohort study.
PLoS One 8:e62683. doi:10.1371/journal.pone.0062683
8. Boardman JP, Waley A, Ball G, Takousis P, Krishnan ML, Hughes-
Carre L, Aljabar P, Serag A et al (2014) Common genetic variants
and risk of brain injury after preterm birth. Pediatrics 133:e1655–
e1663. doi:10.1542/peds.2013-3011
9. Volpe JJ (2009) The encephalopathy of prematurity-brain injury
and impaired brain development inextricably intertwined. Semin.
Pediatr Neurol 16:167–178. doi:10.1016/j.spen.2009.09.005
10. Volpe JJ, Kinney HC, Jensen FE, Rosenberg PA (2011) The devel-
oping oligodendrocyte: key cellular target in brain injury in the
premature infant. Int J Devl Neurosci 29:423–440. doi:10.1016/j.
ijdevneu.2011.02.012
11. Elitt CM, Rosenberg PA (2014) The challenge of understanding
cerebral white matter injury in the premature infant. Neuroscience
276:216–238. doi:10.1016/j.neuroscience.2014.04.038
12. Jensen FE (2005) Role of glutamate receptors in periventricular
leukomalacia. J Child Neurol 20:950–959
13. Danbolt NC (2001) Glutamate uptake. Prog Neurobiol 65:1–105
14. Maragakis NJ, Rothstein JD (2004) Glutamate transporters: animal
models to neurologic disease. Neurobiol Dis 15:461–473. doi:10.
1016/j.nbd.2003.12.007
15. Chao X-D, Fei F, Fei Z (2010) The role of excitatory amino acid
transporters in cerebral ischemia. Neurochem Res 35:1224–1230.
doi:10.1007/s11064-010-0178-3
16. Tanaka K, Watase K, Manabe T, Yamada K, Watanabe M,
Takahashi K, Iwama H, Nishikawa T et al (1997) Epilepsy and
exacerbation of brain injury in mice lacking the glutamate trans-
porter GLT-1. Science 276:1699–1702
17. DeSilva TM, Kinney HC, Borenstein NS, Trachtenberg FL, Irwin
N, Volpe JJ, Rosenberg PA (2007) The glutamate transporter
EAAT2 is transiently expressed in developing human cerebral
white matter. J Comp Neurol 501:879–890. doi:10.1002/cne.21289
18. DeSilva TM, Billiards SS, Borenstein NS, Trachtenberg FL, Volpe
JJ, Kinney HC, Rosenberg PA (2008) Glutamate transporter
EAAT2 expression is up-regulated in reactive astrocytes in human
Mol Neurobiol
periventricular leukomalacia. J Comp Neurol 508:238–248. doi:10.
1002/cne.21667
19. Mallolas J, Hurtado O, CastellanosM, BlancoM, Sobrino T, Serena
J, Vivancos J, Castillo J et al (2006) A polymorphism in the EAAT2
promoter is associated with higher glutamate concentrations and
higher frequency of progressing stroke. J Exp Med 203:711–717.
doi:10.1084/jem.20051979
20. Pampliega O, Domercq M, Villoslada P, Sepulcre J, Rodríguez-
Antigüedad A, Matute C (2008) Association of an EAAT2 poly-
morphism with higher glutamate concentration in relapsing multi-
ple sclerosis. J Neuroimmunol 195:194–198. doi:10.1016/j.
jneuroim.2008.01.011
21. Rajatileka S, Luyt K, Williams M, Harding D, Odd D, Molnár E,
Váradi A (2014) Detection of three closely located single nucleotide
polymorphisms in the EAAT2 promoter: comparison of single-
strand conformational polymorphism (SSCP), pyrosequencing
and Sanger sequencing. BMC Genet 15:80. doi:10.1186/1471-
2156-15-80
22. MacLennan AH, Thompson SC, Gecz J (2015) Cerebral palsy:
causes, pathways, and the role of genetic variants. Am J Obstet
Gynaecol 213:779–788. doi:10.1016/j.ajog.2015.05.034
23. Avon Premature Infant Project (1998) Randomised trial of parental
support for families with very preterm children. Arch Dis Child
Fetal Neonatal Ed 79:F4–11. doi:10.1136/fn.79.1.F4
24. Rajatileka S, Luyt K, El-BokleM,WilliamsM, KempH,Molnár E,
Váradi A (2013) Isolation of human genomic DNA for genetic
analysis from premature neonates: a comparison between newborn
dried blood spots, whole blood and umbilical cord tissue. BMC
Genet 14:105. doi:10.1186/1471-2156-14-105
25. McCarthy KD, de Vellis J (1980) Preparation of separate astroglial
and oligodendroglial cell cultures from rat cerebral tissue. J Cell
Biol 85:890–902
26. Luyt K, Varadi A, Molnar E (2003) Functional metabotropic gluta-
mate receptors are expressed in oligodendrocyte progenitor cells. J
Neurochem 84:1452–1464. doi:10.1046/j.1471-4159.2003.01661.x
27. Luyt K, Slade TP, Dorward JJ, Durant CF, Wu Y, Shigemoto R,
Mundell SJ, Váradi A et al (2007) Developing oligodendrocytes
express functional GABAB receptors that stimulate cell prolifera-
tion and migration. J Neurochem 100:822–840. doi:10.1111/j.
1471-4159.2006.04255.x
28. Bax M, Goldstein M, Rosenbaum P, Leviton A, Paneth N, Dan B,
Jacobsson B, Damiano D et al, Executive Committee for the
Definition of Cerebral Palsy (2005) Proposed definition and classi-
fication of cerebral palsy, April 2005. Dev Med Child Neurol 47:
571–576
29. de Vries LS, Eken P, Dubowitz LM (1992) The spectrum of
leukomalacia using cranial ultrasound. Behav Brain Res 49:1–6
30. Huntley M (1996) The Griffiths Mental Development Scales: from
birth to 2 years. Association for Research in Infant and Child
Development (ARICD). Oxford, UK: The Test Agency 1996:5–39.
31. Bayley N (1993) Manual for the Bayley scales of infant development,
2nd edition edn. Psychological Corporation, San Antonio, Texas
32. Bayley N (2006) Bayley scales of infant development, 3rd edition
edn. Harcourt Assessment, San Antonio, Texas
33. Odd DE, Lewis G, Whitelaw A, Gunnell D (2009) Resuscitation at
birth and cognition at 8 years of age: a cohort study. Lancet 373:
1615–1622. doi:10.1016/S0140-6736(09)60244-0
34. Sun D, Ostermaier MK, Heydenreich FM, Mayer D, Jaussi R,
Standfuss J, Veprintsev DB (2013) AAscan, PCRdesign and
MutantChecker: a suite of programs for primer design and sequence
analysis for high-throughput scanning mutagenesis. PLoS One 8:
e78878. doi:10.1371/journal.pone.0078878
35. SpangaroM, BosiaM, Zanoletti A, BechiM, Cocchi F, PirovanoA,
Lorenzi C, Bramanti P et al (2012) Cognitive dysfunction and glu-
tamate reuptake: effect of EAAT2 polymorphism in schizophrenia.
Neurosci Lett 522:151–155. doi:10.1016/j.neulet.2012.06.030
36. Shin HE, Han SJ, Lee KS, Park JW (2011) Polymorphism of the
glutamate transporter protein EAAT2 and migraine transformation
into chronic daily headache. J Clin Neurol 7:143–147. doi:10.3988/
jcn.2011.7.3.143
37. Feng J, Fouse S, Fan G (2007) Epigenetic regulation of neural gene
expression and neuronal function. Pediatr Res 61:58R–63R. doi:10.
1203/pdr.0b013e3180457635
38. Lister R, Mukamel EA, Nery JR, Urich M, Puddifoot CA, Johnson
ND, Lucero J, Huang Yet al (2013) Global epigenomic reconfigu-
ration during mammalian brain development. Science 341:
1237905. doi:10.1126/science.1237905
39. Spiers H, Hannon E, Schalkwyk LC, Smith R, Wong CC,
O'Donovan MC, Bray NJ, Mill J (2015) Methylomic trajectories
across human fetal brain development. Genome Res 25:338–352.
doi:10.1101/gr.180273.114
40. EndresM,Meisel A, Biniszkiewicz D, Namura S, Prass K, Ruscher
K, Lipski A, Jaenisch R et al (2000) DNA methyltransferase con-
tributes to delayed ischemic brain injury. J Neurosci 20:3175–3181
41. Zschocke J, Allritz C, Engele J, Rein T (2007) DNA methylation
dependent silencing of the human glutamate transporter EAAT2
gene in glial cells. Glia 55:663–674. doi:10.1002/glia.20497
42. Yang Y, Gozen O, Vidensky S, RobinsonMB, Rothstein JD (2010)
Epigenetic regulation of neuron-dependent induction of astroglial
synaptic protein GLT1. Glia 58:277–286. doi:10.1002/glia.20922
43. Sparrow S, Manning JR, Cartier J, Anblagan D, Bastin ME, Piyasena
C, Pataky R, Moore EJ et al (2016) Epigenomic profiling of preterm
infants reveals DNA methylation differences at sites associated with
neural function. Transl Psychiatry 6:e716. doi:10.1038/tp.2015.210
44. de Vivo L, Melone M, Rothstein JD, Conti F (2010) GLT-1 pro-
moter activity in astrocytes and neurons of mouse hippocampus and
somatic sensory cortex. Front Neuroanat 3:31. doi:10.3389/neuro.
05.031.2009
45. Fern R, Möller T (2000) Rapid ischemic cell death in immature
oligodendrocytes: a fatal glutamate release feedback loop. J
Neurosci 20:34–42
46. Back SA, Craig A, Kayton RJ, Luo NL, Meshul CK, Allcock N,
Fern R (2007) Hypoxia-ischemia preferentially triggers glutamate
depletion from oligodendroglia and axons in perinatal cerebral
white matter. J Cereb Blood Flow Metab 27:334–347. doi:10.
1038/sj.jcbfm.9600344
47. Mitani A, Tanaka K (2003) Functional changes of glial glutamate
transporter GLT-1 during ischemia: an in vivo study in the hippo-
campal CA1 of normal mice and mutant mice lacking GLT-1. J
Neurosci 23:7176–7182
48. Andiman SE, Haynes RL, Trachtenberg FL, Billiards SS, Folkerth
RD, Volpe JJ, Kinney HC (2010) The cerebral cortex overlying
periventricular leukomalacia: analysis of pyramidal neurons.
Brain Pathol 20:803–814. doi:10.1111/j.1750-3639.2010.00380.x
49. DeSilva TM, Borenstein NS, Volpe JJ, Kinney HC, Rosenberg PA
(2012) Expression of EAAT2 in neurons and protoplasmic astro-
cytes during human cortical development. J Comp Neurol 520:
3912–3932. doi:10.1002/cne.23130
50. Wood NS, Marlow N, Costeloe K, Gibson AT, Wilkinson AR
(2000) Neurologic and developmental disability after extremely
preterm birth. EPICure study group. N Engl J Med 343:378–384.
doi:10.1056/NEJM200008103430601
51. Miller SP, Cozzio CC, Goldstein RB, Ferriero DM, Partridge JC,
Vigneron DB, Barkovich AJ (2003) Comparing the diagnosis of
white matter injury in premature newborns with serial MR imaging
and transfontanel ultrasonography findings. AJNR Am J
Neuroradiol 24:1661–1669
52. Marlow N (2004) Neurocognitive outcome after very preterm birth.
Arch Dis Child Fetal Neonatal Ed 89:F224–F228
53. Mitchell PJ, Timmons PM, Hébert JM, Rigby PW, Tjian R (1991)
Transcription factor AP-2 is expressed in neural crest cell lineages
during mouse embryogenesis. Genes Dev 5:105–119
Mol Neurobiol
